Expected and verified benefits from old and new corticosteroid treatments in IgA nephropathy: from trials in adults to new IPNA-KDIGO guidelines.

ABSTRACT: IgA nephropathy in children has a potential progression risk over decades of adult life. For this reason, pediatric nephrologists tend to treat the disease from the onset, aiming at halting the pathogenetic processes, based on expert opinion and general confidence with steroids for the lack of large pediatric controlled studies. Glucocorticosteroids are widely used, although without full comprehension of the fine molecular effects on IgAN, mostly based on trials performed in adults. In this review, a critical analysis of adult data is provided for extrapolating information useful for children, with a parallel evaluation of the results of the TESTING Trial, employing oral methylprednisolone, and of the NEFIgArd Trial, using enteric release budesonide. Patients' characteristics and the schem

SUBMITTER: Peruzzi L 

PROVIDER: S-EPMC12116737 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature